The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 February 2026•

1 min read

Hikma Pharmaceuticals Shares Plunge 16% on Weak 2026 Financial Guidance

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Key Facts

1Hikma Pharmaceuticals shares fell 16% to 1,390p.

22025 results were in line with forecasts, but 2026 guidance was weaker than expected.

Hikma Pharmaceuticals PLC saw its shares tumble by 16% to 1,390p following the release of its latest financial outlook. While the company's 2025 results met analyst expectations, its guidance for 2026 fell significantly short of market forecasts. This disappointing outlook overshadowed the announcement of a share buyback program, triggering a sharp sell-off among investors. Alongside the financial update, the company announced that Executive Chair Said Darwazah will assume the role of full-time CEO for the next two years. Additionally, CFO Khalid Nabilsi has been appointed as Deputy CEO to support the leadership transition. Analysts suggest that the double-digit decline reflects deep investor concern over future growth prospects and the conservative earnings targets provided.